These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Pharmacology of the carcinoid syndrome. Lancet; 1968 Feb; 1(7539):404-5. PubMed ID: 4169981 [No Abstract] [Full Text] [Related]
15. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. Lyseng-Williamson KA Drugs; 2018 Jun; 78(9):941-950. PubMed ID: 29931594 [TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical effects of parachlorophenylalanine in a patient with the carcinoid syndrome. Bax ND; Boulton AJ; Woods HF; Green AR Postgrad Med J; 1982 Aug; 58(682):493-5. PubMed ID: 6215640 [TBL] [Abstract][Full Text] [Related]
17. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of phenylalanine hydroxylation during treatment of carcinoid syndrome with p-chlorophenylalanine. Szeinberg A; Shani M; Crispin M; Hirshorn N; Cohen BE; Sheba C Isr J Med Sci; 1970; 6(4):475-8. PubMed ID: 5472331 [No Abstract] [Full Text] [Related]
20. Telotristat ethyl: a new option for the management of carcinoid syndrome. Lamarca A; Barriuso J; McNamara MG; Hubner RA; Valle JW Expert Opin Pharmacother; 2016 Dec; 17(18):2487-2498. PubMed ID: 27817224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]